HotSpot Therapeutics achieves first-in-human dosing with HST-1011, an investigational oral small molecule Allosteric Inhibitor of CBL-B Clinical Impact Apr 11 Written By Frances Benson https://www.hotspotthera.com/press_release/hotspot-therapeutics-achieves-first-in-human-dosing-with-hst-1011-an-investigational-oral-small-molecule-allosteric-inhibitor-of-cbl-b/ 2023 Frances Benson
HotSpot Therapeutics achieves first-in-human dosing with HST-1011, an investigational oral small molecule Allosteric Inhibitor of CBL-B Clinical Impact Apr 11 Written By Frances Benson https://www.hotspotthera.com/press_release/hotspot-therapeutics-achieves-first-in-human-dosing-with-hst-1011-an-investigational-oral-small-molecule-allosteric-inhibitor-of-cbl-b/ 2023 Frances Benson
